Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease

by Corey A. Siegel, Gil Y. Melmed
Published 2009-07-01

Quality indicators in inflammatory bowel disease

by Sameer K. Berry, Gil Y. Melmed
Published 2018-01-01

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay

by Konstantinos Papamichael, Valerio J. Thomas, Andrea Banty, William T. Clarke, Katharine A. Germansky, Sarah N. Flier, Joseph D. Feuerstein, Gil Y. Melmed, Adam S. Cheifetz
Published 2020-09-01

Ultraviolet A light effectively reduces bacteria and viruses including coronavirus.

by Ali Rezaie, Gabriela G S Leite, Gil Y Melmed, Ruchi Mathur, Maria Jesus Villanueva-Millan, Gonzalo Parodi, Jon Sin, Juliana F Germano, Walter Morales, Stacy Weitsman, Seung Young Kim, Jae Ho Park, Siamak Sakhaie, Mark Pimentel
Published 2020-01-01

cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events

by Tara C. Hitzeman, Yu Xie, Ronit H. Zadikany, Andriana P. Nikolova, Rachel Baum, Rachel Baum, Ana-Maria Caldaruse, Sosse Agvanian, Gil Y. Melmed, Dermot P. B. McGovern, Dael R. Geft, David H. Chang, Jaime D. Moriguchi, Antoine Hage, Babak Azarbal, Lawrence S. Czer, Michelle M. Kittleson, Jignesh K. Patel, Alan H. B. Wu, Jon A. Kobashigawa, Michele Hamilton, TingTing Hong, Robin M. Shaw
Published 2020-05-01